arterial-2) with no fatalities. Six (85%) of seven subsequent venous events were unprovoked deep vein thromboses (DVT), with two patients having concomitant pulmonary emboli; whereas one patient developed portal vein thrombosis. Two patients with prior venous events had recurrent DVT in spite of being on therapeutic anticoagulation. Both arterial events were acute coronary syndromes that occurred in patients with additional CV risk factors. Testing for hereditary and acquired thrombophilia was performed in five of six patients with DVT and was negative in all cases.
Whole-exome sequencing (WES) and genotyping of individual colonies revealed the clonal architecture during disease evolution and implicated TET2 and ASXL1 variants as early or germline events.
CASE DESCRIPTION
A 77-year-old man presented with fever and 16 kg weight loss. Clinical examination was unremarkable without splenomegaly. The white blood cell (WBC) count was 270 000/μl, with a myeloid left shift; hemoglobin was 9 g/dl and platelets were 55 000/μl (Supplementary Table 1 ). Bone marrow (BM) biopsy was 90% cellular with a left shift (Figures 1a and b) . BM metaphase karyotyping was 46XY, t(9;22)(q34;q11.2)[20] and blood BCR-ABL1 mRNA (e13a2) was 10% on the international scale (IS). The patient was started on 400 mg imatinib (considered day 1) and stayed on the same dose throughout the treatment. On day 67, partial hematological response was demonstrated, but a rise of monocytes was noted (Supplementary Table 1 ). At day 92, the WBC count rose to 73 000/μl, monocytes were 19%, hemoglobin was 9 g/dl and platelets were 80 000/μl. BM histology showed increased monocytes (Figures 1c and d Table 3 ). In addition, we identified one nonsense variant in ASXL1 (c.24422delC → p.P808fs*10) and two nonsense variants in TET2 (TET2 c.1219delT → p.S407fs*20; c.4932delA → p.Y1645fs*50). Across all samples, including CD3 + and diagnostic CD14 + cells, ASXL1 c.24422delC and TET2 c.4932delA were detected at~50%, whereas TET2 c.1219delT was detected at~30% (Supplementary Table 3 ). ASXL1 c.24422delC and TET2 c.1219delT are listed in catalogue of somatic mutations in cancer and have been confirmed as somatic, whereas our findings are consistent with germline mutations or acquisition by a multipotent hematopoietic stem cell. Although TET2 c4932delA has not been reported in the catalogue of somatic mutations in cancer (COSMIC), a very similar variant (COSM4170135, c.4928delC, p.P1644fs*51) has. WES of the diagnostic sample at an average depth of 319 × failed to identify additional mutations specific to the CML clone, but confirmed the presence of low-level EZH2 In the diagnostic sample, 92/100 colonies were informative for BCR-ABL1 and all for DNA mutational analysis. Only 38% of informative colonies were BCR-ABL1-positive. This is unusual, as myeloid colonies from newly diagnosed CML patients are almost exclusively BCR-ABL1-positive, 5 but is consistent with the low BCR-ABL1 expression (10% IS). Altogether 14% of colonies were positive for at least one of the four somatic SNVs, all of which were BCR-ABL1-negative; 43% were wild type (Figure 2a) (Figure 2a) . The failure of WES and MassARRAY to detect the SNVs in the diagnostic sample likely reflects their lower sensitivity; alternatively, in vitro culture with cytokines may favor CMML colonies owing to their GM-CSF (granulocyte-macrophage colony-stimulating factor) hypersensitivity. 6 No BCR-ABL1-positive colonies were detected on day 67, indicating effective CML therapy; however, 51/105 colonies (49%) were positive for at least one of the four SNVs. Most of the genotypes followed the patterns of the diagnostic sample (Figure 2a, lower panel) ; two colonies were KRAS G12R /NTRK3 V443I / EZH2 I669M and one was heterozygous MSLN P462H . Despite the increase of colonies with at least one SNV, the ratio between the various SNVs remained largely stable (Figure 2a) (Figure 2a ). Altogether, these data are consistent with somatic acquisition of KRAS G12R , followed by NTRK3 V443I and MSLN
P462H
, and finally EZH2 I669M (Figure 2b ). Whether MSLN P462H and NTRK3 V443I were acquired successively or simultaneously cannot be distinguished. KRAS G12R /NTRK3 V443I /EZH2 I669M colonies could reflect loss of the mutant MSLN allele in a side clone, or a sequencing error, which would also explain detection of MSLN P462H as the only SNV in two colonies. As colony assays may skew clonal ratios present in vivo, we quantified KRAS G12R , MSLN P462H , NTRK3 V443I and EZH2 I669M by pyrosequencing of MNCs from all five samples (Figure 2c) . None of the SNVs was detected at diagnosis. KRAS G12R occurred with at least 10% higher allelic frequency than the other SNVs in all subsequent samples, consistent with the initial acquisition. EZH2 I669M was 10-15% higher than MSLN
. This is at variance with the colony data suggesting EZH2 I669M was acquired last, but could be explained by MSLN P462H loss from the clone harboring all four mutations (Figure 2b) , via deletion or acquired uniparental disomy of the non-mutated allele. As shown in Figure 2a , we observed such a clone at low frequency in the colony assays (two colonies in the day 67 and 78 samples). Discrepancies in clonal representation between colony and sequencing data were also demonstrated in AML. 7 Although the presentation of our patient was consistent with CML, low hemoglobin and platelets were unusual in the absence of other high-risk CML features. On imatinib, the clinical phenotype rapidly morphed to CMML and four somatic point mutations were detected by WES of CD14 + cells on day 67. Although neither MassARRAY nor pyrosequencing had identified any of these variants at diagnosis, their rapid appearance suggested they predated imatinib therapy, which was confirmed by colony sequencing. BCR-ABL1 and the CMML-related point mutations may have arisen independently in different hematopoietic stem cells or may share a common abnormal ancestor. The latter is suggested by nonsense SNVs in ASXL1 and TET2, with identical allelic ratios in CD3 + and CD14 + cells, and MNCs, and in all sequential samples, consistent with their presence in the germline or in a pluripotent hematopoietic stem cell. Somatic mutations in CMML T cells have been reported, although typically at a lower allelic ratio than in the myeloid lineage. 8 Verification would require an alternative source of germline DNA, which is not available. Irrespective of this limitation, it is likely that TET2 S407fs*20 and ASXL1 P808fs*10 contribute to CMML in this patient, as they have been reported as validated somatic variants in catalogue of somatic mutations in cancer. Moreover, we have shown that TET2 (~50%) and ASXL1 (~40%) are among the most commonly mutated genes in CMML, whereas the frequency of NRAS or KRAS mutations is only 10-20%. 9 Another study identified TET2 mutations as founder mutations in CMML, 8 while KRAS G12R was as a secondary event, and EZH2 mutations are acquired late. 9 This suggests that RAS G12R and EZH2 I669M were acquired by TET2/ ASXL1-mutant cells. EZH2
I669M is a recurrent CMML mutation and associated with poor outcome. 10 Neither MSLN P462H nor NTRK3
V443I
have been described in CMML or other cancers. MSLN encodes a precursor of two proteins, megakaryocyte potentiation factor, which enhances cytokine effects on megakaryocytes, and mesothelin, a cell adhesion molecule. 11,12 p.P462T was previously reported in esophageal carcinoma. 13 Mutations of NTRK3 (also known as TrkC) have been described in medulloblastoma and other cancers.
14 In AML cell lines, NTRK3 enhances proliferation and inhibits apoptosis through activation of PI3K/AKT and AKT/mTOR. 15 Functional characterization will be required to determine whether MSLN P462H and NTRK3 V443I contribute to disease progression or are bystanders.
Secondary Ph − leukemia after treatment for CML is rare. Prior to the introduction of imatinib, such cases were ascribed to cytotoxic chemotherapy. In the era of TKIs, effective suppression of the highly proliferative Ph + clone may lead to rapid expansion of a previously unrecognized leukemic clone, as in our patient. It is conceivable that a nonspecific agent, such as hydroxyurea, might have been a better option compared with the imatinib/5-azacytidine combination, illustrating the challenges of applying targeted therapy to clonally complex myeloproliferative neoplasms.
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